AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

Pharmaceutical stocks often outperform during market downturns because they pay dividends and their products are mostly ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

It's a good time to take a breather, assess the underlying business, and consider whether the stock's decline offers enough value to make AbbVie a buy despite all this noise. If you've followed ...

In this article, you will learn about extra reasons why I continue to cover AbbVie with a 'Strong Buy' rating. The North Chicago-based company's revenue reached $13.34 billion, and its non-GAAP ...

AbbVie is a Buy and can be a solid addition to any diversified portfolio. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned ...